{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:09:10Z","timestamp":1785434950320,"version":"3.56.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Methionine addiction is a fundamental and general hallmark of cancer caused by enhanced methyl flux. In the present study, we effected a novel methionine-methylation blockade to target a patient-derived orthotopic xenograft model of pancreatic cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The pancreatic cancer patient-derived orthotopic xenograft mouse models were randomized into 6 groups of 8 mice each and treated for 2 weeks: untreated control; azacitidine; oral recombinant methioninase (o-rMETase); o-rMETase plus cycloleucine; o-rMETase plus cycloleucine plus azacitidine (triple-methyl blockade therapy); and gemcitabine (positive control).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Triple-methyl blockade therapy arrested tumor growth (mean relative tumor volume, 1.03 [standard deviation, 0.36]) and was significantly more effective compared with azacitidine (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0001); o-rMETase (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007); or o-rMETase plus cycloleucine (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04). Gemcitabine alone also inhibited but did not arrest tumor growth (mean relative tumor volume, 1.50 [standard deviation, 0.30]). The percentage of cancer cells that were negative for 5-methylcytosine staining in immunohistochemistry, indicating reduction of DNA methylation, increased with triple-methyl blockade therapy (37.5%), compared with gemcitabine (1.8%); o-rMETase (2.8%); azacitidine (9.0%); or o-rMETase plus cycloleucine (10.6%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This new concept of triple-methyl blockade therapy has clinical potential for pancreatic cancer, which is currently a recalcitrant disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000001709","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T19:00:09Z","timestamp":1608058809000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model"],"prefix":"10.1097","volume":"50","author":[{"given":"Norihiko","family":"Sugisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghong","family":"Han","sequence":"additional","affiliation":[{"name":"AntiCancer, Inc, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Tan","sequence":"additional","affiliation":[{"name":"AntiCancer, Inc, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Inubushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bouvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250811","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1073\/pnas.73.5.1523","article-title":"High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine","volume":"73","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib2-20250811","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF02619617","article-title":"Elevated overall rates of transmethylation in cell lines from diverse human tumors","volume":"20","year":"1984","journal-title":"In Vitro"},{"key":"bib3-20250811","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1073\/pnas.76.3.1313","article-title":"Reversion to methionine independence in simian virus 40-transformed human and malignant rat fibroblasts is associated with altered ploidy and altered properties of transformation","volume":"76","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib4-20250811","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jcp.1041190106","article-title":"Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines","volume":"119","year":"1984","journal-title":"J Cell Physiol"},{"key":"bib5-20250811","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/biom10040568","article-title":"Methionine dependence of cancer","volume":"10","year":"2020","journal-title":"Biomolecules"},{"key":"bib6-20250811","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/prep.1996.0700","article-title":"Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy","volume":"9","year":"1997","journal-title":"Protein Expr Purif"},{"key":"bib7-20250811","first-page":"2583","article-title":"Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase","volume":"58","year":"1998","journal-title":"Cancer Res"},{"key":"bib8-20250811","first-page":"2157","article-title":"Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice","volume":"5","year":"1999","journal-title":"Clin Cancer Res"},{"key":"bib9-20250811","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/15384101.2017.1405195","article-title":"Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention","volume":"17","year":"2018","journal-title":"Cell Cycle"},{"key":"bib10-20250811","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.canlet.2018.06.016","article-title":"Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer","volume":"432","year":"2018","journal-title":"Cancer Lett"},{"key":"bib11-20250811","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbrc.2019.08.051","article-title":"Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model","volume":"518","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"bib12-20250811","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-019-03986-0","article-title":"The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model","volume":"85","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib13-20250811","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1073\/pnas.89.12.5645","article-title":"A metastatic nude-mouse model of human pancreatic cancer constructed of orthotopically with histologically intact patient specimens","volume":"89","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib14-20250811","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ijc.2910530414","article-title":"Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors","volume":"53","year":"1993","journal-title":"Int J Cancer"},{"key":"bib15-20250811","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","year":"1980","journal-title":"Cell"},{"key":"bib16-20250811","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1073\/pnas.81.22.6993","article-title":"Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine","volume":"81","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib17-20250811","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1158\/1078-0432.CCR-06-2076","article-title":"DNA methylation as a therapeutic target in cancer","volume":"13","year":"2007","journal-title":"Clin Cancer Res"},{"key":"bib18-20250811","first-page":"50","article-title":"S-adenosylmethionine limitation induces p38 mitogen-activated protein kinase and triggers cell cycle arrest in G1","volume":"127","year":"2014","journal-title":"J Cell Sci"},{"key":"bib19-20250811","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0026-895X(25)11359-X","article-title":"Structural and conformational analogues of L-methionine as inhibitors of the enzymatic synthesis of S-adenosyl-L-methionine. IV. Further mono-, bi- and tricyclic amino acids","volume":"15","year":"1979","journal-title":"Mol Pharmacol"},{"key":"bib20-20250811","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jcp.1040970311","article-title":"Methionine metabolism in BHK cells: preliminary characterization of the physiological effects of cycloleucine, an inhibitor of s-adenosylmethionine biosynthesis","volume":"97","year":"1978","journal-title":"J Cell Physiol"},{"key":"bib21-20250811","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/nprot.2009.171","article-title":"Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice","volume":"4","year":"2009","journal-title":"Nat Protoc"},{"key":"bib22-20250811","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-019-05146-7","article-title":"S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells","volume":"175","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"bib23-20250811","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","year":"2012","journal-title":"Nat Methods"},{"key":"bib24-20250811","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0006-291X(82)91663-1","article-title":"Hypomethylation of HeLa cell DNA and the absence of 5-methylcytosine in SV40 and adenovirus (type 2) DNA: analysis by HPLC","volume":"107","year":"1982","journal-title":"Biochem Biophys Res Commun"},{"key":"bib25-20250811","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bjc.1980.210","article-title":"Effect of methionine deprivation on methylation and synthesis of macromolecules","volume":"42","year":"1980","journal-title":"Br J Cancer"},{"key":"bib26-20250811","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1073\/pnas.79.14.4248","article-title":"Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells","volume":"79","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib27-20250811","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41591-019-0423-5","article-title":"Methionine is a metabolic dependency of tumor-initiating cells","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"bib28-20250811","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41586-019-1437-3","article-title":"Dietary methionine influences therapy in mouse cancer models and alters human metabolism","volume":"572","year":"2019","journal-title":"Nature"},{"key":"bib29-20250811","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.77.12.7306","article-title":"Reversible growth arrest in simian virus 40-transformed human fibroblasts","volume":"77","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib30-20250811","first-page":"717","article-title":"Human tumors are methionine dependent in vivo","volume":"15","year":"1995","journal-title":"Anticancer Res"},{"key":"bib31-20250811","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccell.2019.12.002","article-title":"Vitamin B6 addiction in acute myeloid leukemia","volume":"37","year":"2020","journal-title":"Cancer Cell"},{"key":"bib32-20250811","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.18632\/oncotarget.2369","article-title":"Selective methioninase-induced trap of cancer cells in S\/G2 phase visualized by FUCCI imaging confers chemosensitivity","volume":"5","year":"2014","journal-title":"Oncotarget"},{"key":"bib33-20250811","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-03-0068","article-title":"Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates","volume":"10","year":"2004","journal-title":"Clin Cancer Res"},{"key":"bib34-20250811","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.21873\/anticanres.14254","article-title":"Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methionine in a high-stage ovarian cancer patient","volume":"40","year":"2020","journal-title":"Anticancer Res"},{"key":"bib35-20250811","doi-asserted-by":"crossref","first-page":"13000","DOI":"10.1073\/pnas.1917362117","article-title":"Enzyme-mediated depletion of serum l-met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity","volume":"117","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib36-20250811","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/14712598.2015.963050","article-title":"Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey","volume":"15","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"bib37-20250811","first-page":"4685","article-title":"Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis","volume":"62","year":"2002","journal-title":"Cancer Res"},{"key":"bib38-20250811","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","year":"2002","journal-title":"J Clin Oncol"},{"key":"bib39-20250811","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib40-20250811","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/oxfordjournals.annonc.a058216","article-title":"5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group","volume":"3","year":"1992","journal-title":"Ann Oncol"},{"key":"bib41-20250811","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","year":"2012","journal-title":"Cancer Cell"},{"key":"bib42-20250811","first-page":"21","article-title":"Comparison of doxorubicin with cycloleucine in the treatment of sarcomas","volume":"65","year":"1981","journal-title":"Cancer Treat Rep"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:03:04Z","timestamp":1754956984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001709","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"value":"1536-4828","type":"electronic"},{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}